Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (131-140 of 425) with videos related to

Pageof 43
Sort By:
Kardiologia Polska|January 8, 2025
Primary and secondary cardiovascular prevention: Recent advancesMaciej Banach, Peter P Toth, Agata Bielecka-Dąbrowa, et al.
JACC. Case Reports|October 23, 2023
Distinguishing Lysosomal Acid Lipase Deficiency From Familial HypercholesterolemiaSohum Sheth, Peter P Toth, Seth J Baum, et al.
Progress in Cardiovascular Diseases|May 11, 2015
Is the Guideline Process Replicable and, if Not, What Does This Mean?Allan Sniderman, Curt D Furberg, Peter P Toth, et al.
Journal of Clinical Lipidology|January 24, 2012
Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolismMatthew Konerman, Krishnaji Kulkarni, Peter P Toth, et al.
Journal of Clinical Lipidology|February 5, 2011
Lipid therapy utilization rates in a managed-care mixed dyslipidemia populationPeter P Toth, Victoria Zarotsky, Jane M Sullivan, et al.
Cardiovascular Diabetology|May 20, 2009
Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysisPeter P Toth, Victoria Zarotsky, Jane M Sullivan, et al.
Journal of Clinical Lipidology|July 28, 2012
Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groupsMatthew Konerman, Krishnaji Kulkarni, Peter P Toth, et al.
Journal of Clinical Lipidology|September 29, 2016
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoBAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Lipids in Health and Disease|September 19, 2019
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysisPeter P Toth, Craig Granowitz, Michael Hull, et al.
Journal of Clinical Lipidology|November 6, 2017
What is sufficient drug therapy for lipoprotein elevations?William Virgil Brown, Alan S Brown, Peter P Toth, et al.
Pageof 43

Showing results (131-140 of 425) with videos related to

Sort By:
Pageof 43
Kardiologia Polska|January 8, 2025
Primary and secondary cardiovascular prevention: Recent advancesMaciej Banach, Peter P Toth, Agata Bielecka-Dąbrowa, et al.
JACC. Case Reports|October 23, 2023
Distinguishing Lysosomal Acid Lipase Deficiency From Familial HypercholesterolemiaSohum Sheth, Peter P Toth, Seth J Baum, et al.
Progress in Cardiovascular Diseases|May 11, 2015
Is the Guideline Process Replicable and, if Not, What Does This Mean?Allan Sniderman, Curt D Furberg, Peter P Toth, et al.
Journal of Clinical Lipidology|January 24, 2012
Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolismMatthew Konerman, Krishnaji Kulkarni, Peter P Toth, et al.
Journal of Clinical Lipidology|February 5, 2011
Lipid therapy utilization rates in a managed-care mixed dyslipidemia populationPeter P Toth, Victoria Zarotsky, Jane M Sullivan, et al.
Cardiovascular Diabetology|May 20, 2009
Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysisPeter P Toth, Victoria Zarotsky, Jane M Sullivan, et al.
Journal of Clinical Lipidology|July 28, 2012
Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groupsMatthew Konerman, Krishnaji Kulkarni, Peter P Toth, et al.
Journal of Clinical Lipidology|September 29, 2016
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoBAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Lipids in Health and Disease|September 19, 2019
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysisPeter P Toth, Craig Granowitz, Michael Hull, et al.
Journal of Clinical Lipidology|November 6, 2017
What is sufficient drug therapy for lipoprotein elevations?William Virgil Brown, Alan S Brown, Peter P Toth, et al.
Pageof 43